GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,398.00GBp
30 Oct 2014
Price Change (% chg)

-- (--)
Prev Close
1,398.00p
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
9,529,433
52-wk High
1,709.00p
52-wk Low
1,296.50p

GSK.L

Chart for GSK.L

About

GlaxoSmithKline plc (GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. GSK’s principal pharmaceutical products include medicines in... (more)

Overall

Beta: 0.51
Market Cap (Mil.): £67,824.01
Shares Outstanding (Mil.): 4,849.77
Dividend: 19.00
Yield (%): 5.72

Financials

  GSK.L Industry Sector
P/E (TTM): 16.30 33.49 34.41
EPS (TTM): 0.86 -- --
ROI: 16.65 18.10 17.37
ROE: 75.96 18.76 18.18
Search Stocks

Swiss test GSK Ebola vaccine in some volunteers going to Africa

GENEVA - Switzerland's drug regulator said on Tuesday it had approved the testing of an experimental Ebola vaccine from GlaxoSmithKline on healthy volunteers, some of whom will be traveling to West Africa as medical staff.

28 Oct 2014

Swiss test GSK Ebola vaccine in some volunteers going to Africa

GENEVA, Oct 28 - Switzerland's drug regulator said on Tuesday it had approved the testing of an experimental Ebola vaccine from GlaxoSmithKline on healthy volunteers, some of whom will be travelling to West Africa as medical staff.

28 Oct 2014

UPDATE 2-Novartis results top forecasts as new products gain momentum

* Shares up 2.2 percent (Adds details, CEO quote, shares)

28 Oct 2014

Fitch: GSK Plans Show Possible Shareholder-Friendly Policy Shift

(The following statement was released by the rating agency) LONDON, October 27 (Fitch) GlaxoSmithKline's proposal to float part of its HIV drugs unit highlights a potential shift towards more shareholder-friendly financial policies, which could hurt the group's credit profile, Fitch Ratings says. GSK hasn't provided any details on its plan. But the group's weak share price performance and negative news about its drug sales and bribery investigations in China increase the risk that it would

27 Oct 2014

Exclusive: Advent, Avista near deal for UCB's Kremers Urban - sources

- A consortium of buyout firms Advent International Corp and Avista Capital Partners is in advanced talks to acquire UCB SA's U.S. generic drugs unit Kremers Urban Pharmaceuticals Inc, according to people familiar with the matter.

22 Oct 2014

UPDATE 6-Drugmakers to join forces to make millions of Ebola vaccine doses

* GlaxoSmithKline sees first vaccine doses ready this year

22 Oct 2014

GSK eyes prime FTSE 100 slot for standalone HIV drugs business

LONDON - GlaxoSmithKline , battered by weak U.S. drug sales and a bribery scandal in China, is looking to float its fast-growing HIV drugs business as part of a recovery plan that includes a fresh round of cost cutting. | Video

22 Oct 2014

Motor insurers help Britain's FTSE to end higher

LONDON, Oct 22 - Britain's top share index ended higher on Wednesday, with motor insurers advancing on news of an increase in car premiums and drugmaker GlaxoSmithKline rising after its results.

22 Oct 2014

Motor insurers help Britain's FTSE to end higher

LONDON, Oct 22 - Britain's top share index ended higher on Wednesday, with motor insurers advancing on news of an increase in car premiums and drugmaker GlaxoSmithKline rising after its results.

22 Oct 2014

UPDATE 2-GSK eyes prime FTSE 100 slot for standalone HIV drugs business

* Company going through "painful" period as Advair slides

22 Oct 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Stock Traders Daily
$20.00
Provider: Pechala's Reports
$25.00
Provider: Pechala's Reports
$15.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks